Jennifer Michaelson Sells 1,780 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jennifer Michaelson sold 1,780 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $14.14, for a total transaction of $25,169.20. Following the sale, the insider owned 174,844 shares in the company, valued at approximately $2,472,294.16. This trade represents a 1.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Jennifer Michaelson also recently made the following trade(s):

• On Tuesday, February 24th, Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.47, for a total value of $52,106.47.
• On Monday, February 23rd, Jennifer Michaelson sold 1,752 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $13.99, for a total value of $24,510.48.
• On Friday, February 20th, Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.08, for a total value of $165,327.36.
• On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $5,004.48.
• On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.30, for a total value of $49,200.00.
• On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $10.01, for a total value of $13,463.45.
• On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $9.67, for a total value of $28,023.66.
• On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $11,840.50.
• On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.38, for a total transaction of $26,592.24.

Cullinan Therapeutics Stock Up 5.9%

NASDAQ CGEM traded up $0.85 on Thursday, hitting $15.21. 820,187 shares of the stock were exchanged, compared to its average volume of 732,579. Cullinan Therapeutics, Inc. has a fifty-two week low of $5.68 and a fifty-two week high of $15.23. The company has a market cap of $898.61 million, a PE ratio of -4.60 and a beta of -0.09. The company has a 50-day moving average price of $11.50 and a 200-day moving average price of $9.31.

Cullinan Therapeutics News Summary

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Near-zero reported short interest: a MarketBeat summary flags 0 shares short as of Feb. 25 — if accurate, this removes a potential source of forced selling and can limit downside pressure. Read More
• Neutral Sentiment: Analyst coverage is mixed but tilted positive: multiple firms (Guggenheim, Citi, HC Wainwright) maintain buy ratings and a materially higher average target (~$29.33), while a few shops trimmed ratings — this creates upside narrative but also dispersion in expectations. Read More
• Neutral Sentiment: Recent institutional activity shows increased ownership from several funds (Invesco, Susquehanna, Virtus, Engineers Gate, Elmind Capital), signaling professional interest that can support the stock but may already be priced in. Read More
• Neutral Sentiment: Broader risk sentiment (crypto weakness) noted in the news can pressure small/biotech stocks generally, but this is a market-wide factor rather than company-specific. Read More
• Negative Sentiment: Clustered insider selling: CEO Nadim Ahmed sold 13,515 shares (~$195.6k) at ~$14.47 on Feb. 24 — a meaningful trim that can be viewed negatively by investors. Read More
• Negative Sentiment: Other senior insiders sold the same week (Jeffrey Alan Jones, Jacquelyn L. Sumer): coordinated/clustered sales on Feb. 24 at ~ $14.47 amplify the perception of insider monetization. Read More • Read More
• Negative Sentiment: Director/executive Jennifer Michaelson has made multiple recent sales (Feb. 20–24 and others), trimming her stake across several transactions — adds to the insider-selling narrative. Read More

Hedge Funds Weigh In On Cullinan Therapeutics

Hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. grew its holdings in shares of Cullinan Therapeutics by 1,665.9% during the third quarter. Assenagon Asset Management S.A. now owns 177,685 shares of the company’s stock worth $1,054,000 after buying an additional 167,623 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Cullinan Therapeutics in the second quarter valued at $84,000. Voss Capital LP boosted its position in shares of Cullinan Therapeutics by 43.8% during the 2nd quarter. Voss Capital LP now owns 251,717 shares of the company’s stock worth $1,895,000 after purchasing an additional 76,717 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Cullinan Therapeutics by 0.4% during the 2nd quarter. Franklin Resources Inc. now owns 2,228,160 shares of the company’s stock worth $16,778,000 after purchasing an additional 8,399 shares during the period. Finally, Corton Capital Inc. increased its holdings in shares of Cullinan Therapeutics by 28.9% in the 2nd quarter. Corton Capital Inc. now owns 21,712 shares of the company’s stock valued at $163,000 after purchasing an additional 4,870 shares in the last quarter. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on CGEM shares. Wedbush raised their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. HC Wainwright increased their price objective on Cullinan Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Morgan Stanley restated an “overweight” rating and set a $30.00 target price on shares of Cullinan Therapeutics in a research note on Thursday, January 8th. New Street Research set a $26.00 price target on Cullinan Therapeutics in a report on Thursday, November 20th. Finally, Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.